| abstract |
The present invention provides a class of KCNQ potassium channel agonists with the structure represented by the following general formula I and pharmaceutically acceptable salts thereof, as well as their preparation methods and uses in the preparation of medicines for treating neurological diseases and the like. The compound of the present invention has the same or better therapeutic effect than the compound Retigabine in the prior art, is easier to synthesize and store, and is less prone to oxidative deterioration. |